HLA-A and melanoma: In 1994, van der Bruggen et al., proved that HLA-A*02 and HLA-A*01-restricted MAGE-3 peptides from two different in vitro patient-derived melanoma cell lines were recognized by cytotoxic T-lymphocytes (CTLs) [126,127].